Biodesix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biodesix (BDSX).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$41Upside to Avg. PT+59.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$27→$38
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$27→$35
Aug 6, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$26→$27
Jun 25, 2026	Roth Capital	Max Masucci	Initiate	Buy	$32
Jun 18, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$22→$27
Jun 15, 2026	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$26
May 5, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$20→$22
Feb 27, 2026	William Blair	Brian Weinstein	Upgrade	Market Perform→Outperform	—
Feb 17, 2026	Canaccord Genuity	Kyle Mikson	Maintained	Buy	$20
Sep 19, 2025	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$30→$20
May 21, 2025	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$3→$2
May 14, 2025	Craig-Hallum	Bill Bonello	PT Cut	Buy	$3→$2
May 14, 2025	Lake Street	Thomas Flaten	PT Cut	Buy	$3→$2
May 14, 2025	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$3→$2
May 14, 2025	William Blair	Brian Weinstein	Downgrade	Outperform→Market Perform	—
Apr 29, 2025	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$4→$3
Sep 16, 2024	Scotiabank	Sung Ji Nam	Initiate	Sector Outperform	$3
Jul 26, 2024	Craig-Hallum	Bill Bonello	Initiate	Buy	$3
May 13, 2024	TD Cowen	Dan Brennan	Initiate	Buy	$3
May 3, 2024	Lake Street	—	Initiate	Buy	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27

HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.

Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $22 to $27.

Benzinga Newsdesk

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26

HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.

Benzinga Newsdesk

Biodesix Inc

Biodesix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35

PRO
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27

PRO
Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26

People Also Watch

People Also Watch

Biodesix Inc

Biodesix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35

PROHC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27

PRORoth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

PROCanaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROHC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26

People Also Watch

People Also Watch

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35

PRO
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27

PRO
Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

PRO
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

PRO
HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26